KR102625061B1 - 과도한 모발 쉐딩의 검출 및 치료 - Google Patents

과도한 모발 쉐딩의 검출 및 치료 Download PDF

Info

Publication number
KR102625061B1
KR102625061B1 KR1020177014272A KR20177014272A KR102625061B1 KR 102625061 B1 KR102625061 B1 KR 102625061B1 KR 1020177014272 A KR1020177014272 A KR 1020177014272A KR 20177014272 A KR20177014272 A KR 20177014272A KR 102625061 B1 KR102625061 B1 KR 102625061B1
Authority
KR
South Korea
Prior art keywords
hair
shedding
minoxidil
treatment
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177014272A
Other languages
English (en)
Korean (ko)
Other versions
KR20170102214A (ko
Inventor
로드니 싱클레어
Original Assignee
삼손 클리니컬 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55856287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102625061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904327A external-priority patent/AU2014904327A0/en
Application filed by 삼손 클리니컬 피티와이 엘티디 filed Critical 삼손 클리니컬 피티와이 엘티디
Priority to KR1020247000993A priority Critical patent/KR20240011239A/ko
Publication of KR20170102214A publication Critical patent/KR20170102214A/ko
Application granted granted Critical
Publication of KR102625061B1 publication Critical patent/KR102625061B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177014272A 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료 Active KR102625061B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247000993A KR20240011239A (ko) 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904327A AU2014904327A0 (en) 2014-10-29 Detection and treatment of excessive hair shedding
AU2014904327 2014-10-29
PCT/AU2015/050682 WO2016065426A1 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000993A Division KR20240011239A (ko) 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료

Publications (2)

Publication Number Publication Date
KR20170102214A KR20170102214A (ko) 2017-09-08
KR102625061B1 true KR102625061B1 (ko) 2024-01-16

Family

ID=55856287

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177014272A Active KR102625061B1 (ko) 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료
KR1020247000993A Ceased KR20240011239A (ko) 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247000993A Ceased KR20240011239A (ko) 2014-10-29 2015-10-29 과도한 모발 쉐딩의 검출 및 치료

Country Status (11)

Country Link
US (2) US10226462B2 (enExample)
EP (2) EP3626244B1 (enExample)
JP (2) JP6915946B2 (enExample)
KR (2) KR102625061B1 (enExample)
CN (2) CN107106560A (enExample)
AU (4) AU2015337807B2 (enExample)
CA (2) CA3003940C (enExample)
ES (2) ES2952159T3 (enExample)
NZ (1) NZ732075A (enExample)
SG (2) SG11201703424WA (enExample)
WO (1) WO2016065426A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015337807B2 (en) 2014-10-29 2017-05-04 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20180189976A1 (en) 2016-12-29 2018-07-05 Michal Kasprzak Analysis unit and system for assessment of hair condition
KR102663164B1 (ko) * 2017-07-12 2024-05-07 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
WO2020056191A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN109674762A (zh) * 2019-03-05 2019-04-26 南京正大天晴制药有限公司 一种度他雄胺及治疗脱发的组合物胶囊
CN110478450B (zh) * 2019-10-09 2021-04-13 北海鑫臻药业有限公司 一种治疗阿尔茨海默病的药物组合物及其应用
CN111110721A (zh) * 2020-01-19 2020-05-08 朱炜 一种毛发防脱再生的复合制剂及其使用方法
CN115136191B (zh) * 2020-02-27 2025-03-25 松下知识产权经营株式会社 图像处理装置及图像处理方法
CA3233426A1 (en) * 2021-09-29 2023-04-06 Animesh SINHA Hair loss therapy
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
IL320492A (en) * 2022-10-25 2025-06-01 Veradermics Incorporated Compositions and methods of use for modified release minoxidil
KR20250034269A (ko) * 2023-09-01 2025-03-11 폴리 인터내셔널 탈모증 치료를 위한 경구 미녹시딜에 대한 경구 보충제용 조성물 및 방법
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
DK0557301T3 (da) * 1990-11-14 1995-07-24 Upjohn Co 5-Fluor-2,4,6-pyrimidintriamin-forbindelser til hindring af håraffald
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
GB2314019B (en) 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
AU2406299A (en) 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
JP2000038340A (ja) 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2003012542A (ja) 2001-06-26 2003-01-15 Toray Ind Inc 発毛促進剤
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2522152A1 (en) 2004-10-07 2006-04-07 Kabushiki Kaisha Sangi Transdermal and transmucosal preparations
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
WO2008067158A2 (en) * 2006-11-13 2008-06-05 Auxagen, Inc. METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
AU2015337807B2 (en) 2014-10-29 2017-05-04 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US9561224B1 (en) 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia
KR102663164B1 (ko) 2017-07-12 2024-05-07 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Joel T. Bamford, A falling out following minoxidil: Telogen effluvium, Journal of the American Academy of Dermatology, 1987, 16, 1, 144-145. (1987.01.31.)*
Virginia C. Fiedler-Weiss, et al., Evaluation of oral minoxidil in the treatment of alopecia areata, Arch. Dermatol., 1987, 123, 1488-1490. (1987.11.30.)*

Also Published As

Publication number Publication date
SG11201703424WA (en) 2017-05-30
AU2015337807B2 (en) 2017-05-04
ES2952159T3 (es) 2023-10-27
AU2018279055A1 (en) 2019-01-17
AU2020203695A1 (en) 2020-06-25
KR20170102214A (ko) 2017-09-08
US20190192513A1 (en) 2019-06-27
NZ732075A (en) 2022-09-30
CA3003940A1 (en) 2016-05-06
EP3626244B1 (en) 2023-06-07
HK1243641A1 (en) 2018-07-20
AU2017210523B2 (en) 2018-11-15
US10226462B2 (en) 2019-03-12
SG10202002705YA (en) 2020-05-28
KR20240011239A (ko) 2024-01-25
ES2773467T3 (es) 2020-07-13
US11116770B2 (en) 2021-09-14
CN107106560A (zh) 2017-08-29
AU2015337807A1 (en) 2017-04-13
JP2017533265A (ja) 2017-11-09
EP3212192B1 (en) 2019-11-20
CN115998740A (zh) 2023-04-25
JP6915946B2 (ja) 2021-08-11
US20170333432A1 (en) 2017-11-23
AU2020203695B2 (en) 2021-09-02
CA3209849A1 (en) 2016-05-06
WO2016065426A1 (en) 2016-05-06
EP3626244A1 (en) 2020-03-25
EP3212192A1 (en) 2017-09-06
AU2017210523A1 (en) 2017-08-17
CA3003940C (en) 2023-10-10
EP3212192A4 (en) 2018-07-04
JP2020109127A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
KR102625061B1 (ko) 과도한 모발 쉐딩의 검출 및 치료
Asghar et al. Telogen effluvium: a review of the literature
Glynis A double-blind, placebo-controlled study evaluating the efficacy of an oral supplement in women with self-perceived thinning hair
Olsen et al. Topical minoxidil in early male pattern baldness
Orfanos Androgenetic alopecia: clinical aspects and treatment
Goldberg et al. Alopecia: Kids are not just little people
RU2431485C2 (ru) Способ лечения нарушений роста волос, таких как облысение по женскому типу, и применяемые в нем композиции
Lubov et al. Central centrifugal cicatricial alopecia in Black men: A case series highlighting key clinical features in this cohort
HK40023042A (en) Oral minoxidil for the treatment of alopecia areata
HK40023042B (en) Oral minoxidil for the treatment of alopecia areata
HK1243641B (en) Oral minoxidil for the treatment of telogen effluvium
Sinclair et al. Fast facts: disorders of the hair and scalp
Mysore et al. Optimal use of topical minoxidil in management of female pattern hair loss in India: an expert opinion
Rebora Changes in Growth and Distribution of Hair Associated with Psychotropic Drug Use: Incidence and Mechanisms
Braun-Falco et al. Diseases of the Hair
Hamzeh et al. Common Causes of Hair Loss
Pereira Treatment of androgenetic alopecia with a marine-based extract of proteins and polysaccharides
Zuuren an, Fedorowicz, Z., & Schoones,.(2016)
Welsh The balding woman
Hoesly et al. Alopecia Areata

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601